Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865694 | 0.88 | PDE4A (0.52) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7352735 | 0.86 | PDE4D (0.53) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL1389102 | 0.80 | PDE4A (0.56) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL984917 | 0.79 | PDE4D (0.57) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL4404449 | 0.77 | PDE4A (0.53) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL6865665 | 0.76 | PDE4A (0.55) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL1028931 | 0.76 | PDE4D (0.74) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7387771 | 0.76 | PDE4A (0.54) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL27521810 | 0.75 | PDE4A (0.60) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL6755454 | 0.75 | PDE4A (0.69) | PDE4APDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0652868-B1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2004-11-10 | — | — | EP | claimed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | claimed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | claimed |
| EP-0652868-B1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2004-11-10 | — | — | EP | disclosed |
| US-6255326-B1 | ANTIINFLAMMATORY AGENT; AUTOIMMUNE DISEASES | AVENTIS PHARMA LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6096768-A | ADMINISTERING A 3, 5, 6-SUBSTITUTED PHENYL COMPOUND FOR THE TREATMENT OF INFLAMMATION AND AUTOIMMUNE DISORDERS | RHONE-POULENC RORER LIMITED (GB) | 2000-08-01 | — | — | US | disclosed |
| US-5935978-A | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | RHONE-POULENC RORER LIMITED (GB) | 1999-08-10 | — | — | US | disclosed |
| US-5840724-A | COMPOUNDS FOR TUMOR NECROSIS FACTOR OR ENZYME INHIBITORS OF PHOSPHODIESTERASES | RHONE-POULENC RORER LIMITED (GB) | 1998-11-24 | — | — | US | disclosed |
| EP-0741707-B1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE POULENC RORER LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| US-5698711-A | INHIBITORS OF TUMOR NECROSIS FACTOR, CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE AND EOSINOPHILS | RHONE-POULENC RORER LIMITED (GB) | 1997-12-16 | — | — | US | disclosed |
| US-5679696-A | FOR INHIBITING TUMOR NECROSIS FACTOR; ENZYME INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1997-10-21 | — | — | US | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |